Skip to main content

Table 2 Absolute event rates for each study

From: Comparison of P2Y12 inhibitors and aspirin in secondary prevention of coronary events: a meta-analysis of RCTs

Study

N(P2Y12)

N(ASA)

Any Bleeding

Stroke

MI

Major Bleeding

Ischaemic Stroke

Hemorrhagic Stroke

All-Cause Death

Any minor gastrointestinal

complications

Cardiac Death

P2Y12(%)

ASA(%)

P2Y12(%)

ASA(%)

P2Y12(%)

ASA(%)

P2Y12(%)

ASA(%)

P2Y12(%)

ASA(%)

P2Y12(%)

ASA(%)

P2Y12(%)

ASA(%)

P2Y12(%)

ASA(%)

P2Y12(%)

ASA(%)

Song 2021

870

1357

15 (1.72)

33(2.43)

6(0.69)

9(0.66)

8(0.92)

28(2.06)

/

/

/

/

/

/

12(1.38)

27(1.99)

/

/

/

/

Koo 2021

2710

2728

61(2.25)

87(3.19)

18(0.66)

43(1.58)

18(0.66)

28(1.03)

33(1.22)

53(1.94)

14(0.52)

26(0.95)

4(0.15)

17(0.62)

51(1.88)

36(1.32)

272(10.04)

320(11.73)

19(0.7)

14(0.51)

Watanabe 2024

1471

1486

103(7)

72(4.85)

30(2.04)

39(2.62)

36(2.45)

58(3.90)

69(4.69)

52(3.5)

21(1.43)

29(1.95)

9(0.61)

10(0.67)

123(8.36)

135(9.08)

/

/

28(1.90)

36(2.42)

Zhao 2018

166

166

21(12.65)

15(9.04)

2(1.20)

4(2.41)

2(1.20)

3(1.81)

/

/

/

/

/

/

/

/

/

/

0(0)

2(1.20)

Schunkert 2019

931

928

45(4.83)

44(4.74)

29(3.11)

24(2.59)

19(2.04)

19(2.05)

30(3.22)

34(3.66)

28(3.01)

21(2.62)

1(0.1)

3(0.32)

/

/

/

/

11(1.18)

13(1.40)

CAPRIE Steering

9577

9566

890(9.29)

890(9.30)

486(5.07)

528(5.51)

255(2.66)

301(3.15)

132(1.38)

149(1.56)

472(4.93)

504(5.27)

14(0.15)

24(0.25)

560(5.85)

571(5.97)

191(1.99)

255(2.67)

53(0.55)

75(0.78)